

Programme brief

Version 6 · 26 September 2026 · Draft for review

NWPharmaTech presents our research programme for people at clinical high risk of psychosis, explaining the clinical need, the science and the people behind it.

The programme centres on **NWPT-SM32300**, an investigational oral cannabidiol formulation, and a planned **Phase 2B study** evaluating dose response, symptoms, safety and tolerability. The website brings together accessible explanations, supporting evidence and programme updates, clearly distinguishing established findings from questions our research aims to answer.

A financing route for the programme is under evaluation: platform-integrated financing is the preferred path, with a conventional register-first placement as the fallback. These are development objectives, not live offering terms. Clinical decisions remain independent of financing, and the effectiveness of NWPT-SM32300 is unproven.

Investigational medicine. NWPT-SM32300 is investigational; not approved by any medicines regulator for any use. Its effectiveness is unproven. This brief is not medical advice and is not an offer of any security or token.

Where the programme stands

Investigational medicine	300 mg oral softgel capsule; highly purified cannabidiol in a self-emulsifying (micellar) lipid formulation; GMP manufacture
Completed	Phase 1 study in 14 healthy volunteers: completed 10 December 2025; database locked 11 March 2026; analysis outputs delivered 30 March 2026. Design: randomised, open-label, three-period crossover; single oral doses of NWPT-SM32300 600 mg and 900 mg, and the licensed cannabidiol oral solution Epidyolex as comparator. Registered as NCT07186283 and ISRCTN25163383. Results have not been published yet.
Current stage	Phase 2B study: Planned. Not recruiting. Protocol being finalised.
Next milestone	Finalisation of the Phase 2B protocol, reported as in progress in February 2026. No date has been announced.
Financing	Preferred path under evaluation: platform-integrated programme financing with a permissioned token at close where feasible; a conventional register-first close remains the fallback. These are development objectives, not live offering terms. No investment is being accepted through this website or through the financing route described here.
Company	NWPharmaTech Ltd, company number 13572461, England and Wales

What is established, and what is not

- **Established:** in an updated meta-analysis, the pooled estimate was that about one in four people at clinical high risk developed psychosis within three years, and most do not; no medicine is licensed for this group; NICE advises against antipsychotics for prevention.
- **Emerging:** small, short studies of other CBD preparations in schizophrenia (mixed results) and in clinical high risk (brain activity, stress response, and one 21-day symptom study).
- **Open:** whether NWPT-SM32300 reduces symptoms, which dose is best, and its safety and tolerability in this population.

Sources, evidence labels and verification dates: www.nwpharmatech.org/evidence · Study milestones and sources: www.nwpharmatech.org/study